secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2022-09-30T23:59:59+00:00
Accession:  0001193125-22-255696
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics director Marwan Sabbagh resigns effective Sept 30, 2022
---------------------------------------------------------------------------

- Dr. Marwan Sabbagh resigned from the Board effective September 30, 2022; no disagreement with company.
- Board granted accelerated vesting of portion of March 14, 2022 stock option for service period.
- Post-termination exercise period for vested stock option extended to 12 months after departure date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312522255696/0001193125-22-255696-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312522255696/d294529d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-255696

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer